HONG KONG – Pfizer Inc. (NYSE:PFE) will partner with Suzhou-based Pegbio Co. Ltd. to develop glucokinase activator (GKA) drugs for China as part of the multinational's strategy of using local partners to further the development of innovative drugs that address unmet needs in China.